In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

The tech trade is proving resilient, even unstoppable, while the firms that gained by helping people lose weight are ...

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers. Download the app ...

I’ve had a very eventful year. At the beginning of 2025, my long-term relationship ended, and after a few months, I decided ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

The Milwaukee Bucks Health and Wellness program is celebrating its one-year anniversary. The free medical program was ...

Linda Yaccarino, the former X CEO who left the social media company in the wake of yet another Elon Musk controversy, has ...

The post, at the company that focuses on care for GLP-1 users, comes after Yaccarino left Elon Musk's X in July.

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...